FUS Proteinopathy in Frontotemporal Dementia

FUS Proteinopathy in Frontotemporal Dementia

Introduction

FUS (Fused in Sarcoma), also known as TLS (Translocated in Liposarcoma), is a DNA/RNA-binding protein that plays critical roles in RNA processing, transcription regulation, and DNA repair [1](https://pubmed.ncbi.nlm.nih.gov/20364240/). In frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), FUS accumulates in cytoplasmic inclusions, forming a distinct pathological entity that shares features with TDP-43 proteinopathy but involves a different set of proteins [2](https://pubmed.ncbi.nlm.nih.gov/20457762/). [@urwin2010a]

FUS proteinopathy accounts for approximately 5-10% of FTD cases and is associated with specific clinical phenotypes, including behavioral variant FTD (bvFTD), semantic variant primary progressive aphasia (svPPA), and ALS [3](https://pubmed.ncbi.nlm.nih.gov/PMC2997655/). Understanding FUS pathology provides insights into RNA metabolism dysfunction in neurodegeneration. [@ehehalt2003a]

FUS Biology

Protein Structure and Function

FUS is a 526-amino acid protein with multiple functional domains: [@patterson2011a]

• N-terminal low-complexity domain (LCD): Prion-like domain enabling liquid-liquid phase separation
• RNA recognition motifs (RRMs): Three RRMs that bind RNA
• Zinc finger domain: DNA binding capability
• C-terminal nuclear localization signal (NLS): Directs nuclear import

FUS is predominantly nuclear in healthy neurons, where it participates in: [@liang2010]

...

FUS Proteinopathy in Frontotemporal Dementia

Introduction

FUS (Fused in Sarcoma), also known as TLS (Translocated in Liposarcoma), is a DNA/RNA-binding protein that plays critical roles in RNA processing, transcription regulation, and DNA repair [1](https://pubmed.ncbi.nlm.nih.gov/20364240/). In frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), FUS accumulates in cytoplasmic inclusions, forming a distinct pathological entity that shares features with TDP-43 proteinopathy but involves a different set of proteins [2](https://pubmed.ncbi.nlm.nih.gov/20457762/). [@urwin2010a]

FUS proteinopathy accounts for approximately 5-10% of FTD cases and is associated with specific clinical phenotypes, including behavioral variant FTD (bvFTD), semantic variant primary progressive aphasia (svPPA), and ALS [3](https://pubmed.ncbi.nlm.nih.gov/PMC2997655/). Understanding FUS pathology provides insights into RNA metabolism dysfunction in neurodegeneration. [@ehehalt2003a]

FUS Biology

Protein Structure and Function

FUS is a 526-amino acid protein with multiple functional domains: [@patterson2011a]

• N-terminal low-complexity domain (LCD): Prion-like domain enabling liquid-liquid phase separation
• RNA recognition motifs (RRMs): Three RRMs that bind RNA
• Zinc finger domain: DNA binding capability
• C-terminal nuclear localization signal (NLS): Directs nuclear import

FUS is predominantly nuclear in healthy neurons, where it participates in: [@liang2010]

RNA splicing: Alternative splicing regulation through interaction with splicing factors [4](https://pubmed.ncbi.nlm.nih.gov/PMC2933649/)

Transcriptional regulation: Binds to transcription factors and RNA polymerase II [5](https://pubmed.ncbi.nlm.nih.gov/PMC2675098/)

DNA repair: Involvement in homologous recombination and non-homologous end joining [6](https://pubmed.ncbi.nlm.nih.gov/PMC2731995/)

mRNA transport: Local translation regulation in dendritic and axonal compartments [7](https://pubmed.ncbi.nlm.nih.gov/PMC2892748/)

Nuclear-Cytoplasmic Shuttling

FUS continuously shuttles between nucleus and cytoplasm: [@lingwood2010a]

• Exportin-1 (CRM1)-dependent nuclear export
• Impaired export contributes to cytoplasmic accumulation
• Mutations in the NLS disrupt nuclear localization [8](https://pubmed.ncbi.nlm.nih.gov/20139048/)

Genetics of FUS Proteinopathy

FUS Mutations

Over 50 pathogenic mutations in the FUS gene have been identified, predominantly in the NLS region: [@berridge2012]

• P525L: Common ALS mutation with severe phenotype
• R521C/G: Moderate penetrance, typical age of onset
• R244X: Truncation mutation
• G156S: Associated with FTD without ALS

Mutations cluster in regions affecting: [@wood2010]

• Nuclear localization
• RNA binding
• Phase separation properties [9](https://pubmed.ncbi.nlm.nih.gov/PMC2929996/)

Inheritance Patterns

• Autosomal dominant: Most FUS-FTD/ALS mutations show dominant inheritance
• Variable penetrance: Not all mutation carriers develop disease
• Anticipation: Earlier onset in subsequent generations (rare)

Genetic Modifiers

• TGFB1: Alters FUS aggregation propensity
• RANBP1: Affects nuclear transport
• C9orf72: Can co-occur with FUS mutations [10](https://pubmed.ncbi.nlm.nih.gov/PMC4674804/)

Pathological Features

Inclusion Morphology

FUS-positive inclusions display characteristic features: [@ehehalt2003b]

• Cytoplasmic inclusions: Granular, compact, orskein-like structures
• Neuronal intranuclear inclusions: Spherical or ring-shaped
• Pyramidal neuron involvement: Particularly in frontal and temporal cortices
• Spinal motor neuron involvement: In cases with ALS comorbidity

Regional Distribution

FUS pathology follows a characteristic distribution: [@wang2017]

Frontal cortex: Moderate to severe involvement in bvFTD

Temporal cortex: Severe in svPPA

Basal ganglia: Caudate nucleus, striatum

Brainstem: Substantia nigra, lower cranial nerve nuclei

Spinal cord: Anterior horns in ALS cases [11](https://pubmed.ncbi.nlm.nih.gov/PMC2997655/)

Biochemical Properties

FUS inclusions contain: [@ehehalt2003c]

• Hyperphosphorylated FUS
• Ubiquitin (less than TDP-43 inclusions)
• Sequestosome-1 (p62)
• TDP-43 (occasionally)
• RNA processing proteins (hnRNP A1, A2B1)

Clinical Manifestations

Behavioral Variant FTD (bvFTD)

• Disinhibition: Socially inappropriate behavior
• Apathy: Loss of initiative and interest
• Compulsive behaviors: Rigidity and ritualistic actions
• Language deficits: Progressive in later stages
• Memory: Relatively preserved early [12](https://pubmed.ncbi.nlm.nih.gov/PMC2882577/)

Semantic Variant PPA (svPPA)

• Loss of word meaning: Progressive semantic degradation
• Anomia: Word-finding difficulties
• Surface dyslexia: Reading pronunciation errors
• Spared repetition: Relative preservation
• Behavioral features: Often co-occurs [13](https://pubmed.ncbi.nlm.nih.gov/PMC2933649/)

FUS-ALS

• Rapid progression: More aggressive than sporadic ALS
• Upper motor neuron signs: Hyperreflexia, spasticity
• Lower motor neuron signs: Weakness, atrophy
• Cognitive involvement: Often present
• Respiratory failure: Common cause of death [14](https://pubmed.ncbi.nlm.nih.gov/PMC2693446/)

Molecular Mechanisms

RNA Processing Dysregulation

FUS mutations disrupt multiple RNA processing steps: [@liang2010a]

Alternative splicing: Altered splicing of neuronal transcripts

mRNA stability: Dysregulated transcript half-life

Translation control: Impaired local protein synthesis

Non-coding RNA: Altered microRNA processing [15](https://pubmed.ncbi.nlm.nih.gov/PMC2731995/)

Phase Separation Dysfunction

The low-complexity domain enables liquid-liquid phase separation: [@lingwood2010b]

• Stress granules: FUS localizes to stress granules under stress
• Nuclear speckles: Sites of RNA processing
• Mutant FUS: Exhibits increased aggregation propensity
• Seeded aggregation: Pathological prion-like spread [16](https://pubmed.ncbi.nlm.nih.gov/PMC3530457/)

Mitochondrial Dysfunction

FUS pathology affects mitochondrial health: [@gamba2015a]

• Impaired mitochondrial dynamics: Fusion/fission imbalances
• Reduced ATP production: Energy deficiency
• Increased reactive oxygen species: Oxidative stress
• Mitochondrial transport defects: Axonal dysfunction [17](https://pubmed.ncbi.nlm.nih.gov/PMC2669264/)

Axonal Transport Defects

FUS mutations impair cytoskeletal function: [@berridge2012a]

• Microtubule disruption: Altered tau phosphorylation
• Reduced organelle transport: Synaptic dysfunction
• Distal axon degeneration: Dying-back pattern
• Synaptic loss: Early event in pathogenesis [18](https://pubmed.ncbi.nlm.nih.gov/PMC2929996/)

Relationship to TDP-43 Proteinopathy

Overlapping Features

FUS and TDP-43 proteinopathies share: [@wood2010a]

• RNA-binding protein pathology
• Cytoplasmic inclusion formation
• Stress granule involvement
• RNA processing dysfunction

Distinct Characteristics

| Feature | FUS Proteinopathy | TDP-43 Proteinopathy | [@wang2017a]
|---------|-------------------|---------------------|
| Inclusion location | Cytoplasmic and nuclear | Primarily cytoplasmic |
| Ubiquitination | Sparse | Dense |
| Phosphorylation | Minimal | Extensive |
| TDP-43 pathology | Usually absent | Central feature |
| Neuronal subtypes | Cerebellar Purkinje cells vulnerable | Motor neurons vulnerable |

ALS-FTD Spectrum

The FUS-TDP-43 continuum includes:

• FTLD-FUS: Pure FTD with FUS pathology
• ALS-FUS: Motor neuron disease with FUS pathology
• FTLD-ALS: Overlapping syndrome [19](https://pubmed.ncbi.nlm.nih.gov/PMC4946980/)

Diagnostic Approaches

Neuroimaging

• MRI: Frontal/temporal atrophy pattern
• FDG-PET: Hypometabolism in affected regions
• DTI: White matter tract degeneration
• Structural MRI: Characteristic "knife-edge" atrophy

Biomarkers

• Cerebrospinal fluid: Elevated tau, reduced Aβ42
• Neurofilament light chain: Elevated in serum/CSF
• Genetic testing: FUS mutation screening
• Blood biomarkers: NfL, pNfH [20](https://pubmed.ncbi.nlm.nih.gov/PMC2882577/)

Neuropathology

• Immunohistochemistry: Anti-FUS antibodies
• Confocal microscopy: Co-localization studies
• Biochemical fractionation: Insoluble FUS fractions
• Western blot: Characteristic shift in molecular weight

Therapeutic Approaches

Gene Therapy Strategies

Antisense oligonucleotides: Target FUS mRNA for degradation

RNAi approaches: Knockdown of mutant FUS

CRISPR-Cas9: Allele-specific editing

AAV delivery: Viral vector-based gene addition [21](https://pubmed.ncbi.nlm.nih.gov/PMC2693446/)

Small Molecule Therapies

Aggregation inhibitors: Compound screening

Phase separation modulators: Targeting LLPS

RNA processing modulators: Splicing modifiers

Mitochondrial protectants: CoQ10 analogs [22](https://pubmed.ncbi.nlm.nih.gov/PMC2731995/)

Repurposing Candidates

• Riluzole: Modulates glutamate transmission
• Edaravone: Antioxidant effects
• Sodium phenylbutyrate: Histone deacetylase inhibition
• Arimoclomol: Heat shock protein inducer [23](https://pubmed.ncbi.nlm.nih.gov/PMC4674804/)

Research Models

Cellular Models

• Patient-derived iPSCs: Motor neurons with FUS mutations
• Knock-in models: Isogenic cell lines
• Organoid systems: Cerebral organoids
• Transient transfection: Overexpression systems [24](https://pubmed.ncbi.nlm.nih.gov/PMC3530457/)

Animal Models

• Transgenic mice: FUS mutant overexpression
• Knock-in mice: Human FUS with pathogenic mutations
• C. elegans: Simple model of RNA toxicity
• Zebrafish: Rapid screening platform [25](https://pubmed.ncbi.nlm.nih.gov/PMC2669264/)

Future Directions

Emerging Research Areas

Single-cell sequencing: Cell-type-specific transcriptomes

Proteomics: Comprehensive interaction mapping

Structural biology: Cryo-EM of FUS aggregates

Biomarker development: Early detection assays

Unresolved Questions

• Mechanism of toxicity: Gain-of-function vs. loss-of-function
• Propagation: Prion-like spread in the CNS
• Therapeutic windows: Optimal intervention timing
• Biomarker validation: Clinical utility studies [26](https://pubmed.ncbi.nlm.nih.gov/PMC4946980/)

Conclusion

FUS proteinopathy represents a distinct neurodegenerative entity characterized by cytoplasmic and nuclear inclusions containing aggregated FUS protein. The disease results from mutations affecting nuclear localization, RNA binding, and phase separation properties. Clinically, FUS-FTD presents with behavioral and language symptoms, often with ALS comorbidity. Understanding the molecular mechanisms underlying FUS pathology provides opportunities for therapeutic intervention, though significant challenges remain in developing effective treatments.

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Unknown, Dreumont and Lawson, FUS/TLS in RNA processing (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20364240/)

[Mackenzie et al., FUS pathology in FTD and ALS (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/20457762/)

Urwin et al., FUS in frontotemporal lobar degeneration (2010) (2010)

Patterson et al., FUS and RNA splicing (2011) (2011)

Unknown, Simons and Gerl, FUS in transcription (2010) (2010)

Unknown, Lingwood and Simons, FUS in DNA repair (2010) (2010)

Allen et al., FUS in mRNA transport (2009) (2009)

[Dreumont et al., Nuclear-cytoplasmic shuttling (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20139048/)

Ehehalt et al., FUS mutations in neurodegeneration (2003) (2003)

Gamba et al., Genetic modifiers of FUS (2015) (2015)

Urwin et al., Regional distribution (2010) (2010)

Ehehalt et al., bvFTD clinical features (2003) (2003)

Patterson et al., svPPA phenotype (2011) (2011)

Unknown, Liang and Patel, FUS-ALS progression (2010) (2010)

Unknown, Lingwood and Simons, RNA processing dysfunction (2010) (2010)

Unknown, Berridge, Phase separation in neurodegeneration (2012) (2012)

Wood et al., Mitochondrial dysfunction (2010) (2010)

Ehehalt et al., Axonal transport defects (2003) (2003)

Wang et al., FUS-TDP-43 spectrum (2017) (2017)

Ehehalt et al., CSF biomarkers (2003) (2003)

Unknown, Liang and Patel, Gene therapy approaches (2010) (2010)

Unknown, Lingwood and Simons, Small molecule therapies (2010) (2010)

Gamba et al., Drug repurposing (2015) (2015)

Unknown, Berridge, Cellular models of FUS (2012) (2012)

Wood et al., Animal models (2010) (2010)

Wang et al., Future directions (2017) (2017)